Call to oncologists and administrators

Article

Community Oncology Alliance calls for action; cuts in cancer care reimbursement would have devastating impact on community practices

As an oncologist and practice administrator, we understand that your time is tighter than ever. However, we ask you to reach out to your Representatives in Congress to sign the Stop Cancer Care Cuts letter that Congressman Israel and colleagues want to send to HHS Secretary and CMS Administrator Berwick. COA has sent out emails about this letter and information on it is on the COA website.

To date, 30 Representatives have agreed to sign the letter. Click here to view the list. Included are 7 out of the 13 Representatives in our state, North Carolina. In addition to practices reaching out to their Representatives, here is what those of us across the state are doing to get every

Representative in North Carolina to sign the letter:
1.    We are sending an email addressed to all of the health legislative staff in every North Carolina congressional office.
2.    In the email we are asking the entire North Carolina congressional delegation to please sign the letter.
3.    We are copying every oncologist and practice administrator we have email addresses for on the email. This shows statewide unity on the issue.
4.    We are following up the email with calls.

This does not take a lot of time but it is very effective. Contact information for all House health legislative staff is on the COA website along with other useful information.
 

As you know, our practices are under a lot of pressure, facing oncology-specific cuts to Medicare reimbursement as well as general Medicare cuts of close to 30% in less than 3-4 months. These reductions impact our private payers basing their payment on Medicare.

If we don’t make our voices heard we can’t expect to stop these cuts or find any relief. Simply put, the squeaky wheel gets the grease. Last year, as a community we were very successful in stopping severe payment cuts to Medicare. We have to keep fighting for our patients and practices.

Please ask you Representatives today to sign the Stop Cancer Care Cuts letter. Feel free to contact either of us if you have any questions or suggestions.

David Eagle, MD
Lake Norman Hematology Oncology
deagle@lakenormanoncology.com

Bo Gamble
Southeastern Medical Oncology Center
bgamble@cancersmoc.com
 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video